{'fraction_non_alphanumeric': 0.02495697074010327, 'fraction_numerical': 0.00774526678141136, 'mean_word_length': 5.9640718562874255, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths).

Vancomycin is a glycopeptide antibiotic used to treat infections caused by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The monitoring of steady-state vancomycin plasma concentrations is recommended to reduce the risk of ototoxicity and nephrotoxicity and to ensure that target therapeutic plasma concentrations are achieved [1–3]. Most current recommendations suggest that vancomycin doses should be adjusted to achieve trough plasma concentrations from 5–20 mg l−1, depending on the severity of the infection and the pathogen being treated [1, 3]. Clinicians therefore rely on accurate plasma concentrations to aid dose adjustments and to ensure optimal patient care. 
 
We present two cases of spurious vancomycin plasma concentrations drawn from central venous implantable catheters (portacaths). Whereas a previous report described spurious vancomycin plasma concentrations drawn from a central catheter [4], this problem does not appear to have been described for vancomycin sampled from portacaths.